SHANGHAI, CHINA et CAMBRIDGE, MASSACHUSETTS, US, die 27 Octobris 2022 - JW Therapeutica (HKEX: 2126), societas independens et innovative biotechnologiam in enucleando, fabricando, et mercaturam cellularum immunotherapyarum, ac 2seventy. Bio (NASDAQ: TSVT), principale societatis immuno-oncology cellae curationis, hodie opportuna nuntiavit societatem ad constituendum translationalem et clinicam cellulam theraphim evolutionis suggestum ad explorandum celerius destinatum. T cell-fundatur immunotherapy producta in continenti Sinensi, Hong Kong (China), et Macao (China).
The initial focus of the collaboration is 2seventy’s MAGE-A4 TCR program in solid tumors, which is being developed as part of a collaboration with Regeneron. MAGE-A4 is a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. The program is designed to develop T cell receptor (TCR) therapies ad curationem MAGE-A4 solidorum tumores positivi.
Ut legere licet: CAR T-Lorem In Sina
“We are delighted to work with 2Seventy bio to jointly develop the MAGE-A4 TCR program and potentially other assets in China,” said Dr. Mark J. Gilbert, Chief Medical Officer of JW Therapeutics. “2Seventy is a top-tier cell therapy company with advanced technologies and a highly experienced team. This alliance will further leverage our world-class integrated capabilities, including translational research and clinical development, and we look forward to accelerating the development of more cell immunotherapy products with breakthrough therapeutic value to serve more patients with cancer in China and potentially worldwide.”
“The true patient benefit of this collaboration lies in the ability to establish additional capabilities to rapidly test, learn, and progress our innovative cell therapy programs,” said Steve Bernstein, chief medical officer, 2Seventy bio. “JW Therapeutics possesses extensive understanding of the unmet medical needs of the population and the regulatory affairs process in China, as well as the clinical development pathways. The opportunity to bring together our distinctive areas of experience to create a differentiated platform supports our goal of bringing new therapies to patients as quickly as possible.”
Ut legere licet: CAR T-Cell Lorem pretium in China
Sub pactionis condicione, 2 septuagesima JW Therapeutica licentiam concederet cellae MAGE-A4 in continenti Sinensi, Hong Kong (China), et Macao (China). JW Therapeutica responsabilis erit progressionis, fabricationis, mercaturae in Sinis. 2 septuagesimus eligitur ut miliaria et regalia in fructibus vectigalibus in Sinis recipiat. Accedit, 2sexaginta septuaginta primae notae clinicae sub cooperatione ad fovendam progressionem in aliis geographiis generatae possunt. Clausula transactionis subicietur approbationi sociorum Therapeuticorum JW aliisque condicionibus usitatis claudendis.
De Mago-A4 Programma
MAGISTER MAGE-A4 membrum MAGISTRI familiae cancer testis antigenis expressum est in multis speciebus tumoris solidi. Programma nostra utitur potentissima TCR inventa in collaboratione nostra MediGene
quae peptidas HLA-MAGE-A4 praesentatas recognoscit et amplius auget potentiam harum T cellulis refectis utentibus nostris CTBR12 TGF-beta "flip" technologiam receptorem, quae effectibus immunosuppressivis TGF-betae in signum activationis pro cellulis T convertit. . Regeneron et 2seventy bio sunt coaequales progressioni sub eorum cooperatione in anno MMXVIII inita.
Ut legere licet: CAR T-Cell illic multa myeloma in Sinis
De JW Therapeutica
JW Therapeutica (HKEX: 2126) societas biotechnologia independentis et innovative est in evolutione, fabricando, et mercatura cellularum immunotherapyarum effectarum, et committitur ut innovatio fiat princeps in cella immunotherapy. Fundata anno 2016, JW Therapeutica mundanum genus suggestum evolutionis in cella immunotherapy aedificavit, necnon productum pipelineum sive hematologicae malignitates et tumores solidi. JW Therapeutica committitur ad eruptionem et qualitatem cellularum immunotherapiarum productorum et spem medendi patientibus in Sinis et in mundo, et inducens progressionem sanam et normatum. Sinarum cellula immunotherapy industria.
De 2Seventy bio
Nomen nostrum, 2 septuagesimum bio, refert cur id agimus quod agimus – TEMPUS. Tempus abscindit Cancer et propositum est operam dare summa celeritate transferendi cogitationem humanam in actum —270 milia passuum per hora — dare populo quo magis tempore servimus. Nos aedificamus principales societatis therapiae immuno-oncologiae cellae, ad inveniendas et explicandas novas therapias quae vere tractationem landscape cancri perturbant.
Cum profunda intellectus humani corporis responsionem immunem ad cellulas tumores et ad therapias cellulas in praxim transferendas, hanc scientiam adhibemus ad therapias cellulosas generationi tradendas quae in amplis malignitatibus hematologicis intendunt, primis FDA probatis. Currus T cell illic multa myelomaac tumores solidi. Investigatio nostra et progressus ponuntur in tradendis therapiis quae ordinantur cum meta "cogitandi" smarter et celerius quam morbo. Ad has fines perficiendas potissimum intentus manemus, germana et authentica nostro "quare" manendo et nostros homines et culturae culmen cotidie mentis servans.
Deinceps-respiciens Denunciationes JW Therapeuticae
The forward-looking statements are based on the management’s expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEX) reports filed by the company. Unless otherwise noted, the company is providing this information as of the date it publicized, and expressly disclaims any duty to update the information contained in the issues and relevant information, or provide any explanation.
Ut legere licet: FUCASO ad plures myeloma curatio
Cautionarium Nota de deinceps-respiciens constitutiones 2seventy bio
Haec deliberatio continet "prospectus enuntiationes" intra sensum privatae Securitatum Litigationis Actus Reformationis anni 1995. Hae propositiones comprehendunt, sed non limitantur ad: sententias de consiliis, consiliis, cogitationibus et exspectationibus quoad progressionem, fabricam vel venditio producti nostri candidati, incluso eventus et expectatus leo de permanentis et cogitationibus clinicis iudiciis pro candidatis nostris productis in Sinis et celeritas qua candidatos illos inducere possumus in orci iudiciis; statements about the efficacy and perceived therapeutic benefits of our product candidates and the potential indications, market opportunities and demand therefor; statements about the strategic plans for 2seventy bio and potential corporate development opportunities; statements regarding the company’s financial condition, and other future financial results; and statements about our ability to execute our strategic priorities.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation; the risk that our plans with respect to the preclinical and clinical development and regulatory approval of our product candidates may not be successfully achieved on the planned timeline, or at all.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2021, as supplemented and/or modified by our most recent Quarterly Report on Form 10-Q and any other filings that we have made or will make with the Securities and Exchange Commission in the future.
All information in this press release is as of the date of the release, and 2seventy bio undertakes no duty to update this information unless required by law.
